SUO 2019: Active Surveillance versus Office Fulguration or Laser Treatment
SUO 2019 management of small, low grade bladder cancer recurrences, risk-adapted management approach for patients with low-grade Ta bladder tumors.
Related Articles
Unveiling the Molecular Hallmarks of Peyronie’s Disease: A Comprehensive Narrative Review – Beyond the Abstract
Peyronie’s Disease, Molecular Hallmarks of Peyronie’s Disease, tyrosine kinase inhibitor, transforming growth factor-beta (TGF-β), Matrix metalloproteinases (MMP) enzymes, Tissue inhibitors of metalloproteinases proteins (TIMP), pirfenidone,…
Primary Retroperitoneal Lymph Node Dissection for Clinical Stage II Seminoma: A Systematic Review and Meta-Analysis of Safety and Oncological Effectiveness – Beyond the Abstract
Testicular cancer, Testicular germ cell tumor (TGCT), Retroperitoneal Lymph Node Dissection (RPLND), pathological lymph node staging, clinical stage (CS) II seminomatous TGCT.
Advancing Holmium Laser Enucleation of the Prostate Outcomes Reporting: An Assessment of Patient-Reported Outcomes in the Literature – Beyond the Abstract
Benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS), Holmium Laser Enucleation of the prostate cancer (HoLEP), Advancing Holmium Laser Enucleation, American Urological Association Symptom…
Tumor Dosimetry in PSMA Therapy: A VISION Substudy Analysis – Ken Herrmann
Oliver Sartor host Ken Herrmann to discuss tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in prostate cancer patients. Dr. Herrmann…
Outcomes and Efficacy of Magnetic Resonance Imaging-Compatible Sacral Nerve Stimulator for Management of Fecal Incontinence: A Multi-Institutional Study – Beyond the Abstract
Fecal Incontinence, Sacral neuromodulation, sacral nerve stimulation (SNS), Sacral Nerve Stimulator for Management of Fecal Incontinence, overactive bladder, InterStim™ device.
Sign up
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and…
ctDNA as a Prognostic Biomarker in Bladder Cancer Treatment Decisions – Nimira Alimohamed
Ashish Kamat speaks with Nimira Alimohamed about the evolution of circulating tumor DNA (ctDNA) in muscle invasive bladder cancer management. Dr. Alimohamed explains that current…
Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021 – Beyond the Abstract
Treatment options for metastatic urothelial carcinoma, cisplatin-based chemotherapy, combination enfortumab vedotin–pembrolizumab, Nivolumab as adjuvant treatment in high-risk muscle-invasive UC.
Medicare Part D Changes Reduce Out-of-Pocket Costs for Prostate Cancer Patients – David Morris
Ruchika Talwar interviews David Morris about changes to Medicare Part D resulting from the Inflation Reduction Act. Dr. Morris discusses how these changes benefit prostate…
Ejaculation-Sparing Enucleation of the Prostate with Thulium: Yag Laser (ES-ThuLEP) Versus Thulium Fiber Laser (ES-ThuFLEP): Outcomes on Sexual Function – Beyond the Abstract
Benign Prostatic Enlargement (BPH), Ejaculation-Sparing Enucleation of the Prostate with Thulium Yag Laser (ES-ThuLEP), Thulium Fiber Laser (ES-ThuFLEPEjaculation-Sparing Enucleation of the Prostate with Thulium Yag…